# _embedded.samples[].characteristics.sample title[].text
Colorectal cancer tissue sample (FFPE) 4

# _embedded.samples[].characteristics.secondary description[].text
CAIRO arm A: capecitabine first line Normal colon mucosa from the same patient as the tumor was used as reference in the aCGH experiments.

# _embedded.samples[].characteristics.sample source name[].text
The CR (common reference) was a mixture of all RNA samples from this microarray study.

# _embedded.samples[].characteristics.sample source name[].text
zGRb mRNA-injected at 1-2 cell stage, dex-injected at 24 hpf, RNA isolated from 20 embryos at 30 hpf

# _embedded.samples[].characteristics.secondary description[].text
Biological replicate 3 of 3: zGRb mRNA/dex

# _embedded.samples[].characteristics.sample title[].text
Colorectal cancer tissue sample (FFPE) 113

# _embedded.samples[].characteristics.secondary description[].text
CAIRO arm A: capecitabine first line Normal colon mucosa from the same patient as the tumor was used as reference in the aCGH experiments.

# _embedded.samples[].characteristics.sample title[].text
Colorectal cancer tissue sample (FFPE) 323

# _embedded.samples[].characteristics.secondary description[].text
CAIRO2 arm A: capecitabine, oxaliplatin and bevacizumab Normal colon mucosa from the same patient as the tumor was used as reference in the aCGH experiments.

# _embedded.samples[].characteristics.sample title[].text
Adult human keratinocyte individual 3, replicate 1

# _embedded.samples[].characteristics.sample title[].text
Colorectal cancer tissue sample (FFPE) 243

# _embedded.samples[].characteristics.secondary description[].text
CAIRO2 arm A: capecitabine, oxaliplatin and bevacizumab Normal colon mucosa from the same patient as the tumor was used as reference in the aCGH experiments.

# _embedded.samples[].characteristics.sample title[].text
Colorectal cancer tissue sample (FFPE) 18

# _embedded.samples[].characteristics.secondary description[].text
CAIRO arm B: capecitabine and irinotecan first line Normal colon mucosa from the same patient as the tumor was used as reference in the aCGH experiments.

# _embedded.samples[].characteristics.secondary description[].text
supplementary TDP1_CHIP-2_peaks.bed Illumina Casava 1.8 sanger base calls

# _embedded.samples[].characteristics.sample source name[].text
Purified Hep3B cells transfected with shRNA expression plasmid shR-749 targeting UNC50 mRNA (NM_014044.5) at 749bp

# _embedded.samples[].characteristics.sample source name[].text
J2 immunoprecipitated from whole worm extract

# _embedded.samples[].characteristics.secondary description[].text
supplementary J2NormalizedCounts.txt Illumina Casava 1.8 sanger base calls

# _embedded.samples[].characteristics.sample source name[].text
Purified Hep3B cells transfected with shRNA expression plasmid shR-467 targeting UNC50 mRNA (NM_014044.5) at 467bp

# _embedded.samples[].characteristics.lab description[].text
Stamatoyannopoulous - University of Washington

# _embedded.samples[].characteristics.secondary description[].text
supplementary polyA_normalizedCounts.txt Illumina Casava 1.8 sanger base calls

# _embedded.samples[].characteristics.sample title[].text
IPCRR 233 involved vs IPCRR 233 uninvolved (merged dyeswaps)

# _embedded.samples[].characteristics.sample title[].text
IPCRR 1009 involved Cy3 vs IPCRR 1009 uninvolved Cy5

# _embedded.samples[].organization[].Name
Institute of animal science and veterinary medicine Shandong academy of agricultural sciences

# _embedded.samples[].characteristics.sample title[].text
HPR (control non-PC) involved Cy3 vs HPR (control non-PC) uninvolved Cy5

# _embedded.samples[].characteristics.sample title[].text
IPCRR 394 involved Cy3 vs IPCRR 394 uninvolved Cy5